HNN3.0
Register
Register
Register

Project cooperationUpdated on 23 December 2025

VIOSync®: An AI-Driven Clinical Decision Support System for Early Risk Detection and Proactive Care

CEO at Aisthesis Medical

London, United Kingdom

About

Aisthesis Medical is a digital health and AI company developing clinically oriented, hospital-grade decision support systems designed to enable earlier detection of patient deterioration and more proactive, personalised care across acute and complex disease settings.

Our flagship platform, VIOSync®, is a cloud-native Software as a Medical Device that leverages advanced machine learning, multimodal data fusion, and longitudinal patient modelling to generate real-time, explainable risk insights directly within clinical workflows. The system is designed to integrate heterogeneous healthcare data sources, including electronic health records, vital signs, laboratory results, and clinical observations, supporting both routine care and high-quality clinical research.

Beyond predictive analytics, Aisthesis Medical focuses on translating AI outputs into clinically actionable guidance, combining early risk stratification with contextual explanations and decision support aligned with evidence-based pathways. This human-centred and safety-first design philosophy is intended to improve trust, adoption, and measurable impact in real-world healthcare environments.

The platform is being developed and validated under a robust regulatory and quality framework, aligned with EU MDR, ISO 13485, IEC 62304, IEC 62366-1, and emerging AI governance requirements. This positions Aisthesis Medical as a strong partner for research and innovation consortia seeking solutions that are not only technologically advanced, but also clinically credible, regulator-ready, and scalable.

We are actively seeking project cooperation opportunities within Horizon Europe and related programmes, particularly in areas addressing:

  • prevention and early identification of disease and deterioration,

  • management of long-term or post-acute conditions,

  • responsible and trustworthy use of AI in healthcare,

  • scaling up validated digital innovations within healthcare systems.

Within a consortium, Aisthesis Medical can contribute as a clinical AI technology partner, work-package lead, or innovation and exploitation partner, offering expertise in AI development and validation, real-world data integration, clinical studies, and translation of research outcomes into deployable healthcare solutions.

Topic

  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health

Type

  • Partner seeks Consortium/Coordinator

Organisation

Aisthesis Medical

Start-up

London, United Kingdom

Similar opportunities

  • Project cooperation

    AI-Driven Digital Health Platform for Predictive, Preventive, and Personalised Care

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults

    Ioannis Gkouzionis

    CEO at Aisthesis Medical

    London, United Kingdom

  • Project cooperation

    Offering expertise in clinical validation of devices and digital health solutions

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Chiara Romano

    Postdoctoral researcher at Università Campus Bio-Medico di Roma

    Rome, Italy

  • Project cooperation

    Multimodal Foundation AI Models for Cardiac and Healthcare Applications

    • Consortium/Coordinator seeks Partners
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Alessandro Perelli

    Lecturer in Artificial Intelligence at University of Glasgow

    Glasgow, United Kingdom